TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05167513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin / Sitagliptin Oral Tablet
Description: Metformin and sitagliptin are oral diabetes medicines that help control blood sugar levels.~Metformin works by decreasing glucose (sugar) production in the liver and decreasing absorption of glucose by the intestines. Sitagliptin works by regulating the levels of insulin your body produces after eating.~Metformin and sitagliptin is a combination medicine that is used together with diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus. metformin and sitagliptin is not for treating type 1 diabetes.
Study: NCT05122533

Intervention type: DIAGNOSTIC_TEST
Intervention: EOS
Description: EOS Micro Dose imaging will be done. SterEOS lower limb alignment reconstruction will be performed measuring the lim length.

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical limb length measurements
Description: Clinical measurement of both lower limbs' length, 3 times in 3 different days by 3 observers.~* bony markers position (heel contour, patella and medial malleolus) in resupinate and side position also~* tape measuring:~  * Spina iliaca anterior superior - medial malleolus~ * umbilicus - medial malleolus~ * greater trochanter - lateral malleolus~ * in standing, sitting, resupinate and side position
Study: NCT00693342

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: immunological adjuvant OPT-821
Description: Given subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: immunological adjuvant OPT-821
Description: Given subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: polyvalent antigen-KLH conjugate vaccine
Description: Given subcutaneously
Study: NCT05668104

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Jing Si Herbal Tea Liquid Packet
Description: The preliminary data demonstrated that the Jing Si Herbal Tea Liquid Packet may improve gastrointestinal symptoms and anxiety in patients with Coronavirus disease 2019(COVID-19). Therefore,this study aims to investigate the impact of the Jing Si Herbal Tea Liquid Packet on psychophysical burden and metabolites of microbiota in patients with FD through a double-blind randomized manner.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Jing Si Herbal Tea Liquid Packet Placebo
Description: Compared with the improvement effect of Jing Si Herbal Tea Liquid Packet, to avoid participants thinking that the improvement is due to psychological effects.
Study: NCT05403528

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modality - 3D-2D
Description: Modality in which items will be presented (via tablet/digital media or as real object). 3D items initially and retention/generalization as 2D

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modality - 2D-3D
Description: Modality in which items will be presented (via tablet/digital media or as real object). 2D items initially and retention/generalization as 3D

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modality - 2D-2D
Description: Modality in which items will be presented (via tablet/digital media or as real object). 2D items initially and retention/generalization as 2D
Study: NCT06238713

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single-port extraperitoneal robotic-assisted radical prostatectomy with Vattikuti Institute Prostatectomy（VIP） techniques
Description: Patients with localized prostate cancer are randomized into this group in a 1:1 ratio and receive single-port extraperitoneal robotic-assisted radical prostatectomy with Vattikuti Institute Prostatectomy（VIP） techniques. The investigators will monitor patients for perioperative data recording, treatment and 1-year follow-up.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multi-port transperitoneal robotic-assisted radical prostatectomy with bilateral intrafascial nerve-sparing techniques
Description: Patients with localized prostate cancer are randomized into this group in a 1:1 ratio and receive multi-port transperitoneal robotic-assisted radical prostatectomy with bilateral intrafascial nerve-sparing techniques. The investigators will monitor patients for perioperative data recording, treatment and 1-year follow-up.
Study: NCT05575336

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ADLIFE intervention
Description: The ADLIFE toolbox will be deployed, used and evaluated in seven healthcare environments to demonstrate the effectiveness of the ADLIFE intervention in clinical real conditions. Patients participating in ADLIFE will have a personalised care plan, created in the ADLIFE toolbox, developed and managed together with their healthcare professionals. PCPMP will be used within clinical sites´ ICT systems to create patient care plans based on most recent clinical data, following clinical evidence. The main task of patients and informal caregivers will be to use the ADLIFE toolbox as part of their healthcare process together with their healthcare professionals.~Patients recruited will use the ADLIFE system during the pilot study (a year). If the proposed sample size is not reached by the start date (Dec. 2022), the recruitment period could be expanded to a maximum of three additional months. Patient's follow-up may range between 9 (March-Nov. 2023) and 12 (Dec. 2022 - Nov. 2023) months.
Study: NCT06050330

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: skin biopsy
Description: Paraffin sections,5 Um thick will be prepared from the skin samples and will be analyzed for light microscopy

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: skin biopsy
Description: Paraffin sections,5 Um thick will be prepared from the skin samples and will be analyzed for light microscopy
Study: NCT06034379

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eSpectacle Clinical prototype (CP1) device
Description: The CP1 device consists of a clear 15° central aperture and projects +9.00D defocused micro-LED lights of approximately 4800 nits illumination to the peripheral retina.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eSpectacle Clinical prototype (CP1) device
Description: The CP1 device consists of a clear 15° central aperture and projects +9.00D defocused micro-LED lights of approximately 4800 nits illumination to the peripheral retina.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.01% atropine
Description: Atropine is a and anticholinergic medication which can be used for dilation and cycloplegia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.01% atropine
Description: Atropine is a and anticholinergic medication which can be used for dilation and cycloplegia.
Study: NCT04865939

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sterile water irrigation
Description: Continuous irrigation of bladder with sterile water during surgery (prior to entry into bladder).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Intravesical gemcitabine instilled into bladder during surgery (drained prior to entry into bladder).
Study: NCT05988710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buccal Buprenorphine 300 mcg
Description: buprenorphine for 300mcg buccal administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buccal Buprenorphine 600 mcg
Description: buprenorphine for 600mcg buccal administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buccal Buprenorphine 900 mcg
Description: buprenorphine for 900mcg buccal administration. Note: This arm has been discontinued as of 06/25/2024 and has been replaced with the 450mcg buprenorphine buccal administration arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buccal Placebo
Description: Placebo for buccal administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Buccal Placebo
Description: Placebo for buccal administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Placebo
Description: Placebo for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Placebo
Description: Placebo for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Placebo
Description: Placebo for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Placebo
Description: Placebo for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Placebo
Description: Placebo for oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral immediate-release oxycodone 10mg
Description: Immediate-release oxycodone for 10 mg oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buccal Buprenorphine 450mcg
Description: buprenorphine for 450mcg buccal administration. Note: This arm has been added to replace the 900mcg buprenorphine buccal administration arm.
Study: NCT05470816

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid 100Mg/ml Inj Vial 10ml
Description: Intervention is from the Tranexamic acid to Reduce Infection after Gastrointestinal Surgery: the TRIGS Trial. A multicentre, pragmatic, double-blind, randomised clinical trial will compare the incidence of surgical site infection and red cell transfusion requirements after IV tranexamic acid and placebo in patients undergoing gastrointestinal surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline
Study: NCT05797155

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CoQuit App - Cognitive Dissonance Based Smoking Cessation + Smoking Cessation Tips
Description: CoQuit App (Cognitive Dissonance Based Smoking Cessation) Use of the CoQuit app, completion of cognitive dissonance activities, sharing of videos with online group, and providing support to other group members

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tips for Smoking Cessation App
Description: App containing daily tips for smoking cessation
Study: NCT05859022

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric By-pass (RYGB) surgery
Description: RYGB procedure requires 1-2 hours of operating time and two to three days length of hospital stay. Use the Kit-RYGB by J\& company.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bariatric Arterial Embolization (BAE) procedure
Description: use of Embosphere Microspheres (EM) that are designed to offer controlled, target embolization.
Study: NCT06036784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBX 1416 (Part A)
Description: Single Ascending subcutaneous (SC) dose of MBX 1416: 10mg, 30mg,100mg, 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBX 1416 (Part B)
Description: Repeated ascending subcutaneous (SC) doses of MBX 1416: 10mg, 30mg, 100mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose or repeated subcutaneous (SC) dose of placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBX 1416 (Part C)
Description: Single subcutaneous (SC) dose of MBX 1416 and the single dose of rosuvastatin and acetaminophen pharmacokinetics. The doses selected for MBX 1416 in Part C will not exceed a dose of 200mg.
Study: NCT05600062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Racecadotril 100 milligram (MG) Oral Capsule
Description: Licensed NEP inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule
Study: NCT06167642

Intervention type: DRUG
Intervention: Ofatumumab
Description: Ofatumumab therapy is part of the patient's clinical care and is not given as part of the study
Study: NCT04769713

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Injection of normal saline in the hepatic hilum for the sham procedure
Description: 15 ml sterile normal saline is injected at the hepatic hilum along the anterior surface of the portal vein within 2cm of the bifurcation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Injection of normal saline in the hepatic hilum for the sham procedure
Description: 15 ml sterile normal saline is injected at the hepatic hilum along the anterior surface of the portal vein within 2cm of the bifurcation.
Study: NCT06032520

Intervention type: BEHAVIORAL
Intervention: FAST
Description: FAST includes around 3 hours of face-to-face direct treatment time weekly and consists of a maximum of 10% online direct treatment time (i.e., treatment via phone, video-calling or texting). The treatment stage of FAST lasts five to nine months depending on the individual goals of the juvenile and the caregiver(s) and is followed by a period of aftercare.
Study: NCT06539533

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pilates training
Description: The Pilates that will be used in this study are articulating bridge, Hundreds, Plank , rolls up, one leg stretch, lift leg supine.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pilates training
Description: The Pilates that will be used in this study are articulating bridge, Hundreds, Plank , rolls up, one leg stretch, lift leg supine.
Study: NCT05914038

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation
Description: Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technology. High and low frequencies of rTMS could modulate the excitability of the cerebral cortex.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation
Description: Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technology. High and low frequencies of rTMS could modulate the excitability of the cerebral cortex.
Study: NCT04962828

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vocabulary based intervention- Non Collaborative
Description: List of 10 words functional words Therapy 3 times a week for 20 minutes Duration = 9 weeks Only with SLP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vocabulary based intervention - Collaborative
Description: List of 10 words functional words Therapy 3 times a week for 20 minutes Duration = 9 weeks With SLP and to be reinforced by teachers in class over the week
Study: NCT06507631

Intervention type: BEHAVIORAL
Intervention: Blended care pirate group
Description: During the blended care pirate group, children will receive training while their less affected arm is in a sling. They will perform play-like activities with their affected arm both on-site and at home.
Study: NCT05539261

Intervention type: DEVICE
Intervention: magnetic resonance image
Description: Imaging data were collected in a strong magnetic field

Intervention type: DEVICE
Intervention: magnetic resonance image
Description: Imaging data were collected in a strong magnetic field

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological scale
Description: Multi dimensional neuropsychological test

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological scale
Description: Multi dimensional neuropsychological test
Study: NCT05112094

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: peripheral magnetic stimulation
Description: peripheral magnetic stimulation at ipsilateral shoulder ((50-80% output, 20-40Hz, pulse duration 3-5 seconds, for 15 minutes) ) + regular physical therapy(shoulder range of motion exercise and stretching 30-40 minutes per day)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy
Description: regular physical therapy(shoulder range of motion exercise and stretching 30-40 minutes per day)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: physical therapy
Description: regular physical therapy(shoulder range of motion exercise and stretching 30-40 minutes per day)
Study: NCT06294015

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20% ASED + AT
Description: Participants receive 20% Autologous Serum Eye Drops prepared by the hospital laboratory from the patients blood, diluted with sterile 0.9% sodium chloride to achieve the desired concentration. These drops are administered 6 times daily in one eye for two months. On top of this intervention is standard artificial tears therapy (Refresh Plus), applied four times daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NS + AT
Description: Participants in the placebo group receive eye drops consisting of sterile 0.9% sodium chloride solution, which serves as the placebo. The placebo solution is administered 6 times daily in one eye for two months. Alongside the placebo drops, participants continue with standard artificial tears therapy (Refresh Plus), applied four times daily throughout the study duration.
Study: NCT04837599

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Discovery TM of Pentax medical on/off in colonoscopy
Description: on the monitor artificial integlligence Discovery can be switched on or off.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Discovery TM of Pentax medical on/off in colonoscopy
Description: on the monitor artificial integlligence Discovery can be switched on or off.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Discovery TM of Pentax medical on/off in colonoscopy
Description: on the monitor artificial integlligence Discovery can be switched on or off.
Study: NCT04788875

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Small bite suturing Technique
Description: Small bite suturing technique with PDS 2.0

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standardised Large Bites Technique
Description: Standardised large bite suturing technique with PDS 2.0
Study: NCT05149573

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed Electromagnetic Field (PEMF) Device
Description: BEMER PEMF device consists of a B. Body (full body mat), B. Pad (targeted pelvic pad), and Control Unit which powers the device. Both B. Body and B. Pad must be plugged in simultaneously into the Control Unit and activated individually. B. Body must be placed on a flat surface (e.g. floor, bed, reclining chair, etc) for best results.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed Electromagnetic Field (PEMF) Device
Description: BEMER PEMF device consists of a B. Body (full body mat), B. Pad (targeted pelvic pad), and Control Unit which powers the device. Both B. Body and B. Pad must be plugged in simultaneously into the Control Unit and activated individually. B. Body must be placed on a flat surface (e.g. floor, bed, reclining chair, etc) for best results.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Pulsed Electromagnetic Field (PEMF) Device
Description: The sham PEMF device appears identical to the BEMER PEMF device, with all of the same components and accessories, but does not emit a pulsed electromagnetic field.
Study: NCT05550714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: general anesthesia
Description: The patients did not use any preoperative sedative drugs and were given sufentanil citrate 0.1-0.2 µg/kg, cisatracurium 0.2 mg/kg and propofol 1.5-2.0 mg/kg during anesthesia induction. After the patients were unconscious, oral endotracheal intubation was performed. Anesthesiologists should continuously monitor PetCO2 and maintain PetCO2 at 30-35 mmHg. During the operation, patients are treated with remifentanil, cisatracurium, and desflurane inhalation at 0.5-1.0 minimum alveolar concentration (MAC). In the MER process, the desflurane concentration is adjusted to maintain 0.5-0.6 MAC. If the desflurane concentration needs to be adjusted to less than 0.5 MAC during MER for various reasons, remedial measures will be implemented.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conscious sedation
Description: A loading dose of DEX 0.5 µg/kg was infused intravenously at a constant speed within 15 min after the patients entered the operating room, and the DEX maintenance dose was infused at 0.2-0.5 µg/kg/h until the end of the first stage (deep-brain stimulation implantation) of the operation. Maintain the BIS value at 60-80.
Study: NCT04858594

Intervention type: OTHER
Intervention: Planned Chemotherapy
Description: standard oncologic supportive care including antibiotic prophylaxis

Intervention type: OTHER
Intervention: Planned Chemotherapy
Description: standard oncologic supportive care including antibiotic prophylaxis
Study: NCT05834790

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Augmented Reality (MAR) for oral health education program
Description: MAR application named MAKAR will be available to download and use for smartphones and tablets. Participants will need to scan QR code to access the content of oral health education program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lecture-based oral health education program
Description: The oral health education program that will be delivered by traditional lecture-based process
Study: NCT05682495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARM A
Description: Subjects will receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR\*2 followed by 7 days washout ，then receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR\*2 followed by 7 days washout and then receive treatment HR20031 FDC 10/100/1000 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARM B
Description: Subjects will receive treatment HR20031 FDC 10/100/1000 mg followed by 7 days washout ，then receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR\*2 followed by 7 days washout and then receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR\*2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARM C
Description: Subjects will receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR\*2 followed by 7 days washout ，then receive treatment HR20031 FDC 10/100/1000 mg followed by 7 days washout and then receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR\*2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARM D
Description: Subjects will receive treatment SHR3824 5 mg\*2+ SP2086 50 mg\*2+ Metformin 500 mg XR\*3 followed by 7 days washout ，then receive treatment SHR3824 5 mg\*2+ SP2086 50 mg\*2+ Metformin 500 mg XR\*3 followed by 7 days washout and then receive treatment HR20031 FDC 5/50/750 mg\*2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARM E
Description: Subjects will receive treatment HR20031 FDC 5/50/750 mg\*2 followed by 7 days washout ，then receive treatment SHR3824 5 mg\*2+ SP2086 50 mg\*2+ Metformin 500 mg XR\*3 followed by 7 days washout and then receive treatment SHR3824 5 mg\*2+ SP2086 50 mg\*2+ Metformin 500 mg XR\*3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARM F
Description: Subjects will receive treatment SHR3824 5 mg\*2+ SP2086 50 mg\*2+ Metformin 500 mg XR\*3 followed by 7 days washout ，then receive treatment HR20031 FDC 5/50/750 mg\*2 followed by 7 days washout and then receive treatment SHR3824 5 mg\*2+ SP2086 50 mg\*2+ Metformin 500 mg XR\*3.